Hazard of all-cause late mortality among 2-year survivors of autologous BMT in childhood, for the entire cohort and lymphoma and neuroblastoma survivors
| Variables . | Multivariable analysis, entire cohort . | Multivariable analysis, HL + NHL . | Multivariable analysis, neuroblastoma . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HRadj . | 95% CI . | P . | HRadj . | 95% CI . | P . | HRadj . | 95% CI . | P . | |
| Sex | |||||||||
| Male | 1.00 | 1.00 | 1.00 | ||||||
| Female | 1.82 | 1.19-2.78 | .006 | 1.69 | 0.76-3.85 | .2 | 3.33 | 1.35-8.33 | .008 |
| Race/ethnicity | |||||||||
| Non-Hispanic white | 1.00 | 1.00 | 1.00 | ||||||
| Hispanic | 1.08 | 0.59-1.99 | .8 | 1.85 | 0.67-5.10 | .2 | 0.77 | 0.21-2.76 | .7 |
| Non-Hispanic black | 1.37 | 0.58-3.26 | .5 | 1.89 | 0.47-7.71 | .4 | — | ||
| Other | 0.38 | 0.05-2.76 | .3 | — | 9.66 | 0.89-105.0 | .06 | ||
| Unknown | 0.51 | 0.08-3.69 | .5 | — | — | ||||
| Age at BMT* | 1.03 | 0.98-1.07 | .3 | 0.96 | 0.89-1.04 | .3 | 1.16 | 1.08-1.25 | <.001 |
| Year of BMT | |||||||||
| <1990 | 1.00 | 1.00 | 1.00 | ||||||
| 1990-1999 | 0.47 | 0.26-0.86 | .01 | 0.82 | 0.30-2.24 | .7 | 0.24 | 0.05-1.32 | .1 |
| 2000-2010 | 0.33 | 0.15-0.73 | .006 | 0.15 | 0.04-0.61 | .007 | 1.15 | 0.17-7.62 | .9 |
| Source of stem cells | |||||||||
| Bone marrow | 1.00 | 1.00 | 1.00 | ||||||
| PBSCs/cord blood | 1.29 | 0.72 2.30 | .4 | 1.12 | 0.44-2.85 | .9 | 0.95 | 0.14-6.60 | 1.0 |
| Primary diagnosis | |||||||||
| HL | 1.00 | 1.00 | |||||||
| NHL | 1.15 | 0.44-3.01 | .8 | 1.39 | 0.43-4.49 | .6 | |||
| ALL | 2.40 | 0.91-6.32 | .08 | ||||||
| AML | 0.36 | 0.13-1.01 | .05 | ||||||
| Neuroblastoma | 2.36 | 0.98-5.71 | .06 | ||||||
| Other malignant disease† | 2.29 | 1.06-4.92 | .03 | ||||||
| Disease status at BMT | |||||||||
| Standard risk of relapse‡ | 1.00 | 1.00 | |||||||
| High risk of relapse | 1.49 | 0.82-2.74 | .2 | 1.53 | 0.68-3.46 | .3 | |||
| Conditioning regimen | |||||||||
| TBI | |||||||||
| No | 1.00 | 1.00 | 1.00 | ||||||
| Yes | 0.58 | 0.29-1.16 | .1 | 0.34 | 0.11-1.03 | .06 | 1.39 | 0.23-8.63 | .7 |
| Variables . | Multivariable analysis, entire cohort . | Multivariable analysis, HL + NHL . | Multivariable analysis, neuroblastoma . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HRadj . | 95% CI . | P . | HRadj . | 95% CI . | P . | HRadj . | 95% CI . | P . | |
| Sex | |||||||||
| Male | 1.00 | 1.00 | 1.00 | ||||||
| Female | 1.82 | 1.19-2.78 | .006 | 1.69 | 0.76-3.85 | .2 | 3.33 | 1.35-8.33 | .008 |
| Race/ethnicity | |||||||||
| Non-Hispanic white | 1.00 | 1.00 | 1.00 | ||||||
| Hispanic | 1.08 | 0.59-1.99 | .8 | 1.85 | 0.67-5.10 | .2 | 0.77 | 0.21-2.76 | .7 |
| Non-Hispanic black | 1.37 | 0.58-3.26 | .5 | 1.89 | 0.47-7.71 | .4 | — | ||
| Other | 0.38 | 0.05-2.76 | .3 | — | 9.66 | 0.89-105.0 | .06 | ||
| Unknown | 0.51 | 0.08-3.69 | .5 | — | — | ||||
| Age at BMT* | 1.03 | 0.98-1.07 | .3 | 0.96 | 0.89-1.04 | .3 | 1.16 | 1.08-1.25 | <.001 |
| Year of BMT | |||||||||
| <1990 | 1.00 | 1.00 | 1.00 | ||||||
| 1990-1999 | 0.47 | 0.26-0.86 | .01 | 0.82 | 0.30-2.24 | .7 | 0.24 | 0.05-1.32 | .1 |
| 2000-2010 | 0.33 | 0.15-0.73 | .006 | 0.15 | 0.04-0.61 | .007 | 1.15 | 0.17-7.62 | .9 |
| Source of stem cells | |||||||||
| Bone marrow | 1.00 | 1.00 | 1.00 | ||||||
| PBSCs/cord blood | 1.29 | 0.72 2.30 | .4 | 1.12 | 0.44-2.85 | .9 | 0.95 | 0.14-6.60 | 1.0 |
| Primary diagnosis | |||||||||
| HL | 1.00 | 1.00 | |||||||
| NHL | 1.15 | 0.44-3.01 | .8 | 1.39 | 0.43-4.49 | .6 | |||
| ALL | 2.40 | 0.91-6.32 | .08 | ||||||
| AML | 0.36 | 0.13-1.01 | .05 | ||||||
| Neuroblastoma | 2.36 | 0.98-5.71 | .06 | ||||||
| Other malignant disease† | 2.29 | 1.06-4.92 | .03 | ||||||
| Disease status at BMT | |||||||||
| Standard risk of relapse‡ | 1.00 | 1.00 | |||||||
| High risk of relapse | 1.49 | 0.82-2.74 | .2 | 1.53 | 0.68-3.46 | .3 | |||
| Conditioning regimen | |||||||||
| TBI | |||||||||
| No | 1.00 | 1.00 | 1.00 | ||||||
| Yes | 0.58 | 0.29-1.16 | .1 | 0.34 | 0.11-1.03 | .06 | 1.39 | 0.23-8.63 | .7 |
HRadj, hazard ratio, adjusted for all given variables in table.
Age included in the model as a continuous variable.
Includes 25 Ewing sarcomas, 11 Wilms tumor, 9 CNS tumors, 4 desmoplastic small round cell tumors, 6 soft tissue sarcoma, 1 ovarian tumor, 1 hepatoblastoma, and 1 multiple myeloma.
Standard risk: first or second complete remission after acute leukemia or lymphoma; all others high risk.